Blood-based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blömeke Lara, Rehn Fabian, Pils Marlene, Kraemer-Schulien Victoria, Cousin Anneliese, Kutzsche Janine, Bujnicki Tuyen, Freiesleben Silka D, Schneider Luisa-Sophie, Preis Lukas, Priller Josef, Spruth Eike J, Altenstein Slawek, Schneider Anja, Fliessbach Klaus, Wiltfang Jens, Hansen Niels, Rostamzadeh Ayda, Düzel Emrah, Glanz Wenzel, Incesoy Enise I, Buerger Katharina, Janowitz Daniel, Ewers Michael, Perneczky Robert, Rauchmann Boris-Stephan, Teipel Stefan, Kilimann Ingo, Laske Christoph, Munk Matthias H, Spottke Annika, Roy Nina, Heneka Michael T, Brosseron Frederic, Wagner Michael, Roeske Sandra, Ramirez Alfredo, Schmid Matthias, Jessen Frank, Bannach Oliver, Peters Oliver, Willbold Dieter
Аннотация
METHODS: In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma.
RESULTS: The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants.
CONCLUSIONS: Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.